Lacey Zimmerman

Dec 8, 2024 | tandfonline.com | Justin Porter |Lacey Zimmerman |Melissa A. Nickles |Sheryl Hoyer

AbstractBackground While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.